The agency has asked drugmaker Lykos Therapeutics to run an additional study on the use of the psychedelic drug in patients with post-traumatic stress disorder, pushing back its next proposal by years.
https://www.wired.com/story/fda-rejects-mdma-ptsd-treatment/